Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases (original) (raw)

• Krause, D.S. & Van Etten, R.A. Tyrosine kinases as targets for cancer therapy. N. Engl. J. Med. 353, 172–187 (2005).
  Article CAS Google Scholar
• Sebolt-Leopold, J.S. & English, J.M. Mechanisms of drug inhibition of signalling molecules. Nature 441, 457–462 (2006).
  Article CAS Google Scholar
• Shaw, R.J. & Cantley, L.C. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 441, 424–430 (2006).
  Article CAS Google Scholar
• Samuels, Y. et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 304, 554 (2004).
  Article CAS Google Scholar
• Samuels, Y. & Velculescu, V.E. Oncogenic mutations of PIK3CA in human cancers. Cell Cycle 3, 1221–1224 (2004).
  Article CAS Google Scholar
• Li, J. et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275, 1943–1947 (1997).
  Article CAS Google Scholar
• Knight, Z.A. & Shokat, K.M. Chemically targeting the PI3K family. Biochem. Soc. Trans. 35, 245–249 (2007).
  Article CAS Google Scholar
• Maira, S.M. et al. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol. Cancer Ther. 7, 1851–1863 (2008).
  Article CAS Google Scholar
• Engelman, J.A. et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316, 1039–1043 (2007).
  Article CAS Google Scholar
• Sergina, N.V. et al. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 445, 437–441 (2007).
  Article CAS Google Scholar
• Haas-Kogan, D.A. et al. Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J. Natl. Cancer Inst. 97, 880–887 (2005).
  Article CAS Google Scholar
• Mellinghoff, I.K. et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N. Engl. J. Med. 353, 2012–2024 (2005).
  Article CAS Google Scholar
• Fan, Q.W. et al. Combinatorial efficacy achieved through two-point blockade within a signaling pathway-a chemical genetic approach. Cancer Res. 63, 8930–8938 (2003).
  CAS PubMed Google Scholar
• Wang, M.Y. et al. Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells. Cancer Res. 66, 7864–7869 (2006).
  Article CAS Google Scholar
• Mohi, M.G. et al. Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs. Proc. Natl. Acad. Sci. USA 101, 3130–3135 (2004).
  Article CAS Google Scholar
• Fan, Q.W. et al. A dual phosphoinositide-3-kinase alpha/mTOR inhibitor cooperates with blockade of epidermal growth factor receptor in PTEN-mutant glioma. Cancer Res. 67, 7960–7965 (2007).
  Article CAS Google Scholar
• Knight, Z.A. & Shokat, K.M. Features of selective kinase inhibitors. Chem. Biol. 12, 621–637 (2005).
  Article CAS Google Scholar
• Knight, Z.A. et al. A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell 125, 733–747 (2006).
  Article CAS Google Scholar
• Karaman, M.W. et al. A quantitative analysis of kinase inhibitor selectivity. Nat. Biotechnol. 26, 127–132 (2008).
  Article CAS Google Scholar
• Hopkins, A.L., Mason, J.S. & Overington, J.P. Can we rationally design promiscuous drugs? Curr. Opin. Struct. Biol. 16, 127–136 (2006).
  Article CAS Google Scholar
• Scheeff, E.D. & Bourne, P.E. Structural evolution of the protein kinase-like superfamily. PLoS Comput. Biol. 1, e49 (2005).
  Article Google Scholar
• Walker, E.H., Perisic, O., Ried, C., Stephens, L. & Williams, R.L. Structural insights into phosphoinositide 3-kinase catalysis and signalling. Nature 402, 313–320 (1999).
  Article CAS Google Scholar
• Walker, E.H. et al. Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine. Mol. Cell 6, 909–919 (2000).
  Article CAS Google Scholar
• Liu, Y. et al. Wortmannin, a widely used phosphoinositide 3-kinase inhibitor, also potently inhibits mammalian polo-like kinase. Chem. Biol. 12, 99–107 (2005).
  Article CAS Google Scholar
• Stauffer, F., Maira, S.M., Furet, P. & Garcia-Echeverria, C. Imidazo[4,5-c]quinolines as inhibitors of the PI3K/PKB-pathway. Bioorg. Med. Chem. Lett. 18, 1027–1030 (2008).
  Article CAS Google Scholar
• Hanke, J.H. et al. Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. Study of Lck- and FynT-dependent T cell activation. J. Biol. Chem. 271, 695–701 (1996).
  Article CAS Google Scholar
• Liu, Y. et al. Structural basis for selective inhibition of Src family kinases by PP1. Chem. Biol. 6, 671–678 (1999).
  Article CAS Google Scholar
• Schindler, T. et al. Crystal structure of Hck in complex with a Src family-selective tyrosine kinase inhibitor. Mol. Cell 3, 639–648 (1999).
  Article CAS Google Scholar
• Sarbassov, D.D., Guertin, D.A., Ali, S.M. & Sabatini, D.M. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307, 1098–1101 (2005).
  Article CAS Google Scholar
• Ishii, N. et al. Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines. Brain Pathol. 9, 469–479 (1999).
  Article CAS Google Scholar
• Fan, Q.W. et al. A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell 9, 341–349 (2006).
  Article CAS Google Scholar
• Samuels, Y. et al. Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell 7, 561–573 (2005).
  Article CAS Google Scholar
• Carlomagno, F. et al. BAY 43–9006 inhibition of oncogenic RET mutants. J. Natl. Cancer Inst. 98, 326–334 (2006).
  Article CAS Google Scholar
• Carlomagno, F. et al. Point mutation of the RET proto-oncogene in the TT human medullary thyroid carcinoma cell line. Biochem. Biophys. Res. Commun. 207, 1022–1028 (1995).
  Article CAS Google Scholar
• Gupta-Abramson, V. et al. Phase II trial of sorafenib in advanced thyroid cancer. J. Clin. Oncol. (in the press).
• Graupera, M. et al. Angiogenesis selectively requires the p110alpha isoform of PI3K to control endothelial cell migration. Nature 453, 662–666 (2008).
  Article CAS Google Scholar
• Guba, M. et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat. Med. 8, 128–135 (2002).
  Article CAS Google Scholar
• de Klein, A. et al. A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia. Nature 300, 765–767 (1982).
  Article CAS Google Scholar
• Shah, N.P. et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2, 117–125 (2002).
  Article CAS Google Scholar
• Gorre, M.E. et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293, 876–880 (2001).
  Article CAS Google Scholar
• Sawyers, C.L. Cancer: mixing cocktails. Nature 449, 993–996 (2007).
  Article CAS Google Scholar
• Stommel, J.M. et al. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 318, 287–290 (2007).
  Article CAS Google Scholar
• Schindler, T. et al. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 289, 1938–1942 (2000).
  Article CAS Google Scholar
• Liu, Y. & Gray, N.S. Rational design of inhibitors that bind to inactive kinase conformations. Nat. Chem. Biol. 2, 358–364 (2006).
  Article CAS Google Scholar
• Dudley, D.T., Pang, L., Decker, S.J., Bridges, A.J. & Saltiel, A.R. A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc. Natl. Acad. Sci. USA 92, 7686–7689 (1995).
  Article CAS Google Scholar
• Fry, D.W. et al. Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor. Proc. Natl. Acad. Sci. USA 95, 12022–12027 (1998).
  Article CAS Google Scholar
• Cohen, M.S., Zhang, C., Shokat, K.M. & Taunton, J. Structural bioinformatics-based design of selective, irreversible kinase inhibitors. Science 308, 1318–1321 (2005).
  Article CAS Google Scholar